ASXL1 and acquired polycythemia vera: We demonstrated that JAK2V617F-positive PV patients harboring mutated ASXL1 exhibited poor myelofibrosis-free survival, and that mutated ASXL1 was present in 25% of post-PV myelofibrosis cases compared with only 4% of PV cases without myelofibrosis.